Drug intelligence / Profile preview

TAK-114

Development stage: Phase 2
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral

Overview

TAK-114 is a synthetic small molecule immunomodulator developed for the treatment of inflammatory diseases and cancer. It acts as a cytokine modulator and inhibits the STAT3 transcription factor, impacting regulatory T lymphocytes and Th17 cells. The drug was investigated primarily for ulcerative colitis but also explored in prostate cancer and systemic lupus erythematosus. Its mechanism involves modulation of immune responses by inhibiting key pro-inflammatory cytokines such as IL1B, IL6, IL12, and TNF. TAK-114 was developed by Natrogen Therapeutics International in collaboration with Takeda Pharmaceuticals International GmbH but has since been discontinued in all indications[1][3].

Other names: MeisoindigoNatura-α

Targets

IL1B (Interleukin-1 beta)STAT3 (Signal Transducer and Activator of Transcription 3)IL-6 (Interleukin 6)

Beyond the preview

Go deeper on TAK-114.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAK-114.

Explore the full profile